Cost-effectiveness Analysis of Adebrelimab Combined with Chemotherapy in First Line Treatment of Extensive Stage Small-cell Lung Cancer
10.13748/j.cnki.issn1007-7693.20231119
- VernacularTitle:阿得贝利单抗联合化疗一线治疗广泛期小细胞肺癌的成本效果分析
- Author:
Yue LI
1
;
Shujia KONG
2
;
Pin ZHAO
1
;
Xuemei WANG
1
;
Liju LIANG
1
;
Zhiying WENG
1
Author Information
1. School of Pharmaceutical Science, Kunming Medical University, Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming 650500, China
2. Yunnan Provincial Tumor Hospital, Kunming 650118, China；School of Pharmaceutical Science, Kunming Medical University, Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming 650500, China
- Publication Type:Journal Article
- Keywords:
adebrelimab；small cell lung carcinoma；cost-utility analysis；pharmaceutical； economics
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(9):1267-1274
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To evaluate the cost-effectiveness of adebrelimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive stage small cell lung cancer from Chinese healthcare system perspective.
METHODS
Using the data obtained from the CAPSTONE-1 trial(230 cases for adebrelimab group, and 232 cases for chemotherapy group), Markov model was created for simulation of the disease development process of the extensive stage small cell lung cancer. The total costs, quality-adjusted life-years(QALYs) and incremental cost-effectiveness ratio(ICER) in each group were calculated. The sensitivity of key parameters was analyzed.
RESULTS
Compared with pure chemotherapy(etoposide plus carboplatin chemotherapy), the ICER of adebrelimab combined with chemotherapy was 157128.79 yuan·QALY−1 under the situation of charity assistance, and 351367.27 yuan·QALY −1 in the environment of no charity assistance. Sensitivity analysis showed that the utility and the cost of adebrelimab were the main influence parameter.
CONCLUSION
Adebrelimab combined with chemotherapy regimen has no cost-effective advantage versus chemotherapy alone in the treatment of extensive stage small cell lung cancer under the current economic level of China; the probability of adebrelimab combined with chemotherapy being cost- effectiveness was 44.5% under the situation of charity assistan.
